Literature DB >> 24063570

Green tea polyphenol decreases the severity of portosystemic collaterals and mesenteric angiogenesis in rats with liver cirrhosis.

Shao-Jung Hsu, Sun-Sang Wang, I-Fang Hsin, Fa-Yauh Lee, Hui-Chun Huang, Teh-Ia Huo, Wen-Shin Lee, Han-Chieh Lin, Shou-Dong Lee.   

Abstract

Abnormal angiogenesis in liver cirrhosis often leads to severe complications such as variceal haemorrhage and encephalopathy. Furthermore, splanchnic angiogenesis elevates portal pressure, in which angiogenic factors play pivotal roles. GTP (green tea polyphenol) extracted from Camellia sinensis has anti-angiogenic properties, but the effects on the parameters described above in cirrhosis have not been investigated. The aim of the present study was to determine the effects of GTP in cirrhosis and to investigate the underlying mechanism. Liver cirrhosis was induced in Spraque-Dawley rats by common BDL (bile duct ligation). They randomly received GTP or DW (distilled water, vehicle) for 28 days, then haemodynamic parameters, portosystemic shunting, mesenteric window vascular density, intrahepatic angiogenesis, liver fibrosis, plasma VEGF (vascular endothelial growth factor) concentration, mesenteric angiogenic factor and receptor protein expression, and serum and mesenteric oxidative stress parameters were assessed. Compared with the DW group, GTP significantly decreased portosystemic shunting, liver fibrosis, intrahepatic angiogenesis, mesenteric window vascular density, VEGF concentration and down-regulated the mesenteric HIF (hypoxia-inducible factor)-1α, VEGF and phospho-Akt expression. In conclusion, GTP ameliorates the severity of portosystemic shunting and mesenteric angiogenesis via the suppression of HIF-1α, Akt activation and VEGF. GTP appears to be an appropriate agent in controlling portal hypertension-related complications via anti-angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24063570     DOI: 10.1042/CS20130215

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  7 in total

Review 1.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.

Authors:  Dmitry Victorovich Garbuzenko
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 3.  Angiogenesis and Hepatic Fibrosis: Western and Chinese Medicine Therapies on the Road.

Authors:  Jing-Si Wang; Qiu-Yun Zhang; Jin-Lian Cheng; Lan-Yu Chen; Nai-Li Yao; Gui-Zhi Sun; Yu-Ling Chu
Journal:  Chin J Integr Med       Date:  2018-06-25       Impact factor: 1.978

Review 4.  New cellular and molecular targets for the treatment of portal hypertension.

Authors:  Jordi Gracia-Sancho; Raquel Maeso-Díaz; Anabel Fernández-Iglesias; María Navarro-Zornoza; Jaime Bosch
Journal:  Hepatol Int       Date:  2015-03-05       Impact factor: 6.047

Review 5.  Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives.

Authors:  Dmitry Victorovich Garbuzenko; Nikolay Olegovich Arefyev; Evgeniy Leonidovich Kazachkov
Journal:  World J Gastroenterol       Date:  2018-09-07       Impact factor: 5.742

6.  Halogenated Flavonoid Derivatives Display Antiangiogenic Activity.

Authors:  Mai Khater; Kimberly A Watson; Samuel Y Boateng; Francesca Greco; Helen M I Osborn
Journal:  Molecules       Date:  2022-07-25       Impact factor: 4.927

Review 7.  Preclinical Models for Investigation of Herbal Medicines in Liver Diseases: Update and Perspective.

Authors:  Hor-Yue Tan; Serban San-Marina; Ning Wang; Ming Hong; Sha Li; Lei Li; Fan Cheung; Xiao-Yan Wen; Yibin Feng
Journal:  Evid Based Complement Alternat Med       Date:  2016-01-28       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.